Medtronic secures two ce mark approvals for guardian 4 sensor & for inpen mdi smart insulin pen

New no fingerstick 1  sensor integrates with both the minimed 780g system and the smart inpen system dublin, may 26, 2021 /prnewswire/ --  medtronic plc (nyse:mdt), the global leader in medical technology, today announced ce (conformitÉ europÉenne) mark for expanded functionality of the company's inpen™ smart2 insulin pen for multiple daily injections (mdi). the company also announced ce mark for its guardian™ 4 sensor3, which requires no fingersticks1 for calibration or diabetes treatment decisions.
MDT Ratings Summary
MDT Quant Ranking